Mr. Brendan Gleeson:

There would be a decision on the optimum products to fund and which could not be funded in any tranche. We have now reached a point in looking at the current tranche where we know we will not be able to fund all of them if we want to continue to be able to run new tranches as time goes on. We have reached that point.